MyPathway Subanalysis Backs Combination HER2-Targeting Antibodies in Colorectal Cancer

Investigators studied a combination of  pertuzumab and trastuzumab in patients with metastatic, HER2-positive colorectal cancer.

Source: CancerNetwork - April 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news